Nanospectra Biosciences, Inc. Raises $1 Million As It Moves Through Clinical Trials
Houston-based Nanospectra Biosciences Inc. has raised nearly $1 million as it moves into a human clinical study, according to a filing with the Securities and Exchange Commission.
The $945,995 is a portion of a $1.2 million capital raise, funded almost exclusively by previous Nanospectra investors, said David Jorden, CEO of Nanaospectra. The cash will go toward funding a human clinical study with three institutions in Houston and New York. Nanospectra is developing a cancer therapy aimed to better radiation and other treatments, according to its website.
The $945,995 is a portion of a $1.2 million capital raise, funded almost exclusively by previous Nanospectra investors, said David Jorden, CEO of Nanaospectra. The cash will go toward funding a human clinical study with three institutions in Houston and New York. Nanospectra is developing a cancer therapy aimed to better radiation and other treatments, according to its website.